Overview on Alzheimer’s Disease
DOI:
https://doi.org/10.18311/ti/2021/v28i4/27338Keywords:
Dementia, Deterioration of Memory, Loss of Cognitive Function, Reactive Microgliosis, Synapses, White MatterAbstract
The world wide spread dementia of Alzeheimer disease is estimated to be as high as 24 million and it is hypothesized to be double every 20 years through 2040 resulting to a costly risk of the disease. Alzehimer disease is the main cause of dementia and is manifested by a gradual loss of cognitive function which is initially begin with deterioration of memory. Before death, the patient is fully dependent on their care givers. The main mechanism underlying the neuropath logical changes in Alzheimer patient are remaining unknown. But mainly they may be affected by both environmental and genetic factors. The hall mark pathology of Alzheimer disease are mainly accompanied by the presence of reactive microgliosis and the loss of neurons, white matter and synapses3.Downloads
Published
How to Cite
Issue
Section
Accepted 2021-11-11
Published 2021-12-22
References
Smith MA. Alzheimer disease. Int Rev Neurobiol. 1998; 42:1– 54. https://doi.org/10.1016/S0074-7742(08)60607-8. DOI: https://doi.org/10.1016/S0074-7742(08)60607-8
Cummings JL, Cole G. Alzheimer disease. JAMA. 2002; 287(18):2335–8. https://doi.org/10.1001/jama.287.18.2335. PMid:11988038.
Braak H, Braak E. Neuropathological stageing of Alzheimerrelated changes. Acta Neuropathol. 1991; 82(4):239–59. https://doi.org/10.1007/BF00308809. PMid:1759558. DOI: https://doi.org/10.1007/BF00308809
Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol. 2011; 7(3):137–52. https://doi.org/10.1038/nrneurol.2011.2. PMid:21304480. PMCid:PMC3339565. DOI: https://doi.org/10.1038/nrneurol.2011.2
Cummings JL, Cole G. Alzheimer disease. JAMA. 2002; 287(18):2335–8. https://doi.org/10.1001/jama.287.18.2335. PMid:11988038. DOI: https://doi.org/10.1001/jama.287.18.2335
Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell. 2012; 148(6):1204–22. https://doi.org/10.1016/j.cell.2012.02.040. PMid:22424230. PMCid:PMC3319071. DOI: https://doi.org/10.1016/j.cell.2012.02.040
Winslow BT, Onysko M, Stob CM, Hazlewood KA. Treatment of Alzheimer disease. Am Fam Physician. 2011; 83(12):1403–12.
Batsch NL, Mittelman MS. World Alzheimer Report 2012. Overcoming the Stigma of Dementia. Alzheimer’s Disease INTERNATIONAL (ADI), London; 2012.
Jonsson T, et al. Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med. 2013; 368(2):107–16. DOI: https://doi.org/10.1056/NEJMoa1211103
Knuesel I, et al. Maternal immune activation and abnormal brain development across CNS disorders. Nat Rev Neurol. 2014; 10(11):643. https://doi.org/10.1038/nrneurol. 2014.187. PMid:25311587. DOI: https://doi.org/10.1038/nrneurol.2014.187
Krstic D, Knuesel, I. Deciphering the mechanism underlying late-onset Alzheimer disease. Nat Rev Neurol. 2013; 9(1):25. https://doi.org/10.1038/nrneurol.2012.236. PMid:23183882. DOI: https://doi.org/10.1038/nrneurol.2012.236
Sosa-Ortiz, AL, Acosta-Castillo I, Prince MJ. Epidemiology of dementias and Alzheimer’s disease. Arch Med Res. 2012; 43(8):600–8. https://doi.org/10.1016/j.arcmed.2012.11.003. PMid:23159715. DOI: https://doi.org/10.1016/j.arcmed.2012.11.003
Bonda DJ, et al. Role of metal dyshomeostasis in Alzheimer’s disease. Metallomics. 2011; 3(3): 267–70. https://doi.org/10.1039/c0mt00074d. PMid:21298161. PMCid:PMC3117398. DOI: https://doi.org/10.1039/c0mt00074d
Van Gorp B, Vercruysse T. Frames and counter-frames giving meaning to dementia: A framing analysis of media content. Soc Sci Med. 2012; 74(8):1274–81. https://doi.org/10.1016/j.socscimed.2011.12.045. PMid:22386639. DOI: https://doi.org/10.1016/j.socscimed.2011.12.045
Melo A, et al. Oxidative stress in neurodegenerative diseases: mechanisms and therapeutic perspectives. Oxid Med Cell Longev. 2011. https://doi.org/10.1155/2011/467180. PMid:22191013. PMCid:PMC3236428. DOI: https://doi.org/10.1155/2011/467180
Christen Y. Oxidative stress and Alzheimer disease. Am J Clin Nutr. 2000; 71(2):621S–9S. https://doi.org/10.1093/ajcn/71.2.621s. PMid:10681270. DOI: https://doi.org/10.1093/ajcn/71.2.621s
Esler WP, Wolfe MS. A portrait of Alzheimer secretases-- new features and familiar faces. Science. 2001; 293(5534):1449–54. https://doi.org/10.1126/science. 1064638. PMid:11520976. DOI: https://doi.org/10.1126/science.1064638
Skoog I, Kalaria RN, Breteler MM. Vascular factors and Alzheimer disease. Alzheimer Dis Assoc Disord. 1999; 13:S106–14. https://doi.org/10.1097/00002093-199912003-00016. PMid:10609689. DOI: https://doi.org/10.1097/00002093-199912003-00016
Larson EB, et al. Survival after initial diagnosis of Alzheimer disease. Annals of internal medicine. 2004; 140(7):501–9. https://doi.org/10.7326/0003-4819-140-7-200404060-00008. PMid:15068977. DOI: https://doi.org/10.7326/0003-4819-140-7-200404060-00008
Engelhart MJ, et al. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA. 2002; 287(24):3223–29. https://doi.org/10.1001/jama.287.24.3223. PMid:12076218. DOI: https://doi.org/10.1001/jama.287.24.3223
De la Torre JC. Alzheimer disease as a vascular disorder: Nosological Evidence. Stroke. 2002; 33(4):1152–62. https://doi.org/10.1161/01.STR.0000014421.15948.67. PMid:11935076. DOI: https://doi.org/10.1161/01.STR.0000014421.15948.67
Kozauer N, Katz R. Regulatory innovation and drug development for early-stage Alzheimer’s disease. N Engl J Med. 2013; 368(13):1169–71. https://doi.org/10.1056/NEJMp1302513. PMid:23484795. DOI: https://doi.org/10.1056/NEJMp1302513
Rafii MS, Aisen PS. Recent developments in Alzheimer’s disease therapeutics. BMC Medicine. 2009; 7(1):1–4. https://doi.org/10.1186/1741-7015-7-7. PMid:19228370. PMCid:PMC2649159. DOI: https://doi.org/10.1186/1741-7015-7-7
Crismon ML. Tacrine: first drug approved for Alzheimer’s disease. Ann Pharmacother. 1994; 28(6):744–51. https://doi.org/10.1177/106002809402800612. PMid:7919566. DOI: https://doi.org/10.1177/106002809402800612
Mayeux R, Sano M. Treatment of Alzheimer’s disease. N Engl J Med. 1999; 341(22):1670–79. https://doi.org/10.1056/NEJM199911253412207. PMid:10572156. DOI: https://doi.org/10.1056/NEJM199911253412207
Molinuevo J L, et al. Current state of Alzheimer’s fluid biomarkers. Acta Neuropathol. 2018; 136(6):821–53. https://doi.org/10.1007/s00401-018-1932-x. PMid:30488277. PMCid:PMC6280827. DOI: https://doi.org/10.1007/s00401-018-1932-x
Behrens S, et al. Use of FDA approved medications for Alzheimer’s disease in mild dementia is associated with reduced informal costs of care. Int Psychogeriatr. 2018; 30(10):1499. https://doi.org/10.1017/S104161021800011X. PMid:29559029. PMCid:PMC6150839. DOI: https://doi.org/10.1017/S104161021800011X
Bassil N, Thaipisuttikul P, Grossberg GT. Memantine ER, a once-daily formulation for the treatment of Alzheimer’s disease. Expert Opin Pharmacother. 2010; 11(10):1765–71. https://doi.org/10.1517/14656566.2010.493874. PMid:20540654. DOI: https://doi.org/10.1517/14656566.2010.493874
Lleo A, Greenberg SM, Growdon JH. Current pharmacotherapy for Alzheimer’s disease. Annu Rev Med. 2006; 57:513–33. https://doi.org/10.1146/annurev.med.57.121304.131442. PMid:16409164. DOI: https://doi.org/10.1146/annurev.med.57.121304.131442
Romero K, et al. The future is now: model?based clinical trial design for Alzheimer’s disease. Clin Pharmacol Ther. 2015; 97(3):210–14. https://doi.org/10.1002/cpt.16. PMid:25669145. PMCid:PMC6463482. DOI: https://doi.org/10.1002/cpt.16